Inclusion Criteria:  Pathologically confirmed myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients with one of the 65 antimonial-treatable p53 mutations with > 5% VAF: Q136P, Y234H, V272M, F270V, P278A, R213L, Y126H, T253N, T253I, R158L, Q136E, P142F, A129D, L194R, R110P, V172G, C176F, I254N, K305R, E285D, T155P, H296D, E258G, G279V, T211A, R213P, C229Y, I232F, E294K, P152R, R196P, M160T, N131S, N131H, K139N, L330H, Y220N, E298Q, D148E, L264R, E224D, H168P, N263H, K320N, S227C, E286D, K292T, V203A, M237R, F212L, K132Q, Y236S, Y126S, Q136H, E221A, I232S, Y163H, P190T, C182Y, P142L, Y163S, V218E, I195S, V272A, and S106R. Life expectancy >12 weeks. ECOG Performance status < 3. Aged from 18 to 75. Active bone marrow hyperplasia indicated by morphology. Normal liver and renal function, bilirubin ≤35μmol/L, ASL/ALT lower than 2xULN, creatinine level ≤150μmol/L. Normal cardiac function. Lung function: dyspnea ≤ CTC AE grade 1 and SaO2≥ 92% in indoor air environment. Written Informed consent.  Exclusion Criteria:  Confirmed CNS involvement. Severe cardiac diseases including myocardial infarction or heart insufficiency. QT interval ≥450ms on ECG. With other visceral malignancy. Active tuberculosis or HIV(+). Patients with pregnancy or lactation. Allergic or significantly contraindicated to any drugs involved in intervention. Previous intolerance or allergy history to similar drugs. Participation at same time in another study in which investigational drugs are used. Any other conditions interfering the study. Abnormal liver function which does not meet the inclusion criteria. ECOG performance status ≥3, CCI >1, ADL <100. Aged <18 years or >75years